Target Price | GBP1.48 |
Price | GBP0.79 |
Potential |
87.29%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Naked Wines 2026 .
The average Naked Wines target price is GBP1.48.
This is
87.29%
register free of charge
GBP2.00
152.53%
register free of charge
GBP0.95
19.95%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend Naked Wines to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Naked Wines stock has an average upside potential 2026 of
87.29%
register free of charge
|
Apr '24 |
2025 Estimates |
|
---|---|---|
Revenue Million GBP | 290.41 | 252.38 |
17.97% | 13.10% | |
EBITDA Margin | 0.35% | 1.73% |
90.90% | 153.74% | |
Net Margin | -7.13% | -0.97% |
42.23% | 86.40% |
3 Analysts have issued a sales forecast Naked Wines 2025 . The average Naked Wines sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Naked Wines EBITDA forecast 2025. The average Naked Wines EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Naked Wines 2025 . The average Naked Wines net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Apr '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share GBP | -0.28 | -0.03 |
16.67% | 89.29% | |
P/E | negative | |
EV/Sales | 0.15 |
1 Analysts have issued a Naked Wines forecast for earnings per share. The average Naked Wines EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.